IRIS
DE PLACIDO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.799
NA - Nord America 2.300
EU - Europa 1.936
SA - Sud America 304
AF - Africa 63
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.405
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.191
SG - Singapore 1.181
RU - Federazione Russa 835
CN - Cina 556
VN - Vietnam 518
IT - Italia 498
BR - Brasile 229
HK - Hong Kong 200
DE - Germania 165
FR - Francia 101
IN - India 87
NL - Olanda 84
FI - Finlandia 69
CA - Canada 68
GB - Regno Unito 60
JP - Giappone 58
KR - Corea 42
AR - Argentina 38
CI - Costa d'Avorio 27
MX - Messico 23
PK - Pakistan 19
ES - Italia 18
PH - Filippine 18
PL - Polonia 17
BD - Bangladesh 14
IQ - Iraq 14
ZA - Sudafrica 14
TH - Thailandia 12
UA - Ucraina 12
CZ - Repubblica Ceca 10
SE - Svezia 10
BE - Belgio 9
ID - Indonesia 9
TR - Turchia 9
TW - Taiwan 9
VE - Venezuela 9
EC - Ecuador 8
RS - Serbia 8
UZ - Uzbekistan 8
AT - Austria 7
EG - Egitto 6
IR - Iran 6
AL - Albania 5
CL - Cile 5
CR - Costa Rica 5
IE - Irlanda 5
JM - Giamaica 5
LT - Lituania 5
AE - Emirati Arabi Uniti 4
MY - Malesia 4
PY - Paraguay 4
UY - Uruguay 4
CO - Colombia 3
CY - Cipro 3
GR - Grecia 3
JO - Giordania 3
KE - Kenya 3
KH - Cambogia 3
LV - Lettonia 3
NP - Nepal 3
SY - Repubblica araba siriana 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
DZ - Algeria 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MN - Mongolia 2
NG - Nigeria 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
MC - Monaco 1
MD - Moldavia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
Totale 7.400
Salva come PNG Salva come JPEG
Città #
Singapore 617
San Jose 511
Ashburn 228
Hefei 195
Moscow 195
Hong Kong 191
Naples 149
Ho Chi Minh City 147
Beijing 145
Chandler 136
Santa Clara 107
Hanoi 103
Dallas 93
Munich 85
Amsterdam 65
Los Angeles 64
Lauterbourg 57
New York 54
Tokyo 52
The Dalles 47
Council Bluffs 43
Kochi 34
Seoul 33
Turku 31
Buffalo 30
Millbury 29
Lawrence 27
Orem 25
Rome 25
Da Nang 24
Frankfurt am Main 23
Haiphong 23
São Paulo 23
Boston 22
Montreal 22
Pune 22
Redondo Beach 22
Lappeenranta 21
Milan 19
Napoli 19
Toronto 18
Des Moines 17
Helsinki 17
Nuremberg 17
Denver 14
Ottawa 14
Brooklyn 13
Mexico City 13
Poplar 13
Seattle 13
Casoria 12
London 12
Belo Horizonte 11
Houston 11
Warsaw 11
Biên Hòa 10
Manchester 10
Shanghai 10
Wilmington 10
Atlanta 9
Chennai 9
Dong Ket 8
Johannesburg 8
Baghdad 7
Bologna 7
Chicago 7
Düsseldorf 7
Stockholm 7
Tashkent 7
Turin 7
Brno 6
Formia 6
Lahore 6
Massa di Somma 6
Ninh Bình 6
Redwood City 6
Vienna 6
Belgrade 5
Boardman 5
Borgomanero 5
Falkenstein 5
Hải Dương 5
Jacksonville 5
Kingston 5
Long Xuyen 5
Phoenix 5
Porto Alegre 5
Rio de Janeiro 5
Salt Lake City 5
Salvador 5
Tirana 5
Brussels 4
Bình Phước 4
Bắc Giang 4
Bến Tre 4
Cairo 4
Can Tho 4
Charlotte 4
Dublin 4
Erbil 4
Totale 4.235
Salva come PNG Salva come JPEG
Nome #
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 206
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 197
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 197
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 195
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 185
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 184
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 178
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor 171
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 167
Prevalence of Sarcopenia in Women with Breast Cancer 161
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 161
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 159
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 159
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 156
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 152
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 151
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 151
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 150
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 148
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 146
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 145
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 145
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 142
Mechanisms of resistance to mTOR inhibitors 142
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 141
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 141
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 139
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 136
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
BRAF Gene and Melanoma: Back to the Future 135
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 135
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 134
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 133
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 128
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 126
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 126
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 122
Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors 120
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 118
Immunological signature of patients with thymic epithelial tumors and Good syndrome 116
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 115
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 114
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 113
Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials 110
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 108
Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response 108
Statin use and survival in patients with metastatic castrationresistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: The international retrospective observational STABEN study 94
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 82
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 67
Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention 58
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis 57
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study 51
The European Reference Network: the keystone for the management of rare thoracic cancers 51
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer 49
Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic 38
Management of Autoimmune Conditions Associated With Thymic Epithelial Tumors 38
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis 37
Ductal Carcinoma In Situ 33
Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges 31
Serum HDL subfractions are impaired by COVID-19 vaccine in patients with thymic epithelial tumors 17
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study 3
Totale 7.536
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 0 18
2021/2022215 6 3 11 7 2 5 11 9 7 22 70 62
2022/2023397 34 34 14 17 36 39 14 43 51 78 21 16
2023/2024407 15 53 59 39 19 57 6 50 8 5 52 44
2024/20252.026 63 69 4 54 70 134 201 132 118 230 777 174
2025/20264.286 418 307 484 375 715 259 591 226 479 292 127 13
Totale 7.536